ClinicalTrials.gg
CompletedNCT07777952Updated Aug 21, 2026

Adjunctive 308-nm Excimer Light With Oral Azithromycin for Inflammatory Acne

An interventional study of 308-nm Excimer Light and Azithromycin in Acne Vulgaris, sponsored by Mahmoud Rageh. Completed at 1 site in Egypt. Open to participants aged 15 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Mahmoud Rageh · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Oct 2025, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
15 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies in Acne Vulgaris with a site in Egypt — 10 open to participants now, 11 under way, 2 of them phase 3. Acne Vulgaris · Egypt.

Enrollment
24th of 31
32 · median 60
Started
2025
with 7 others
No phase
18 of 39
3 open now
Registered
35th of 39
by date

Among the 39 studies in Acne Vulgaris with a site in Egypt, this one is the 24th largest by enrollment of the 31 interventional ones that give a count, is one of 8 that started in 2025, is one of 18 with no phase, and was the 35th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

10 of the 39 studies in Acne Vulgaris with a site in Egypt are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 15 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Acne Vulgaris with a site in Egypt, or all of them as a file.
02

Study summary

This randomized, evaluator-blinded, split-face study evaluated whether adjunctive lesion-directed 308-nm excimer light improves inflammatory acne outcomes during oral azithromycin therapy. All participants received oral azithromycin 500 mg three times weekly for 8 weeks. One randomly allocated hemiface additionally received 308-nm excimer light twice weekly for 8 weeks, while the contralateral hemiface served as the azithromycin-only control. Papule and pustule counts and hemiface Investigator's Global Assessment were assessed through Week 8. Investigator's Global Assessment was reassessed at Week 16 after an 8-week treatment-free follow-up. We hypothesized that the excimer-treated hemiface would demonstrate greater reduction in total inflammatory-lesion count by Week 8.

Read the detailed description

Participants with bilateral inflammatory acne received oral azithromycin 500 mg after meals three times weekly for 8 weeks. One hemiface was randomized by coin toss to receive adjunctive lesion-directed 308-nm excimer light twice weekly for 8 weeks; the contralateral hemiface received no irradiation. The primary outcome was the within-participant between-side difference in change from baseline to Week 8 in total inflammatory lesion count, defined as papules plus pustules. Hemiface IGA was assessed through Week 16, following an 8-week treatment-free period.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Inflammatory acne
  • 308-nm excimer light
  • Azithromycin
  • Phototherapy
  • Split-face
04

Who can participate

Ages eligible
15 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants.
  • age 15-35 years.
  • Bilateral inflammatory acne involving both hemifaces, with clinically comparable baseline inflammatory involvement as assessed before randomization.
  • No topical or systemic acne treatment during the preceding 8 weeks.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy.
  • Photosensitivity disorders.
  • Macrolide .
  • Concurrent isotretinoin use or isotretinoin use during the preceding 8 weeks.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Excimer Light Plus Oral Azithromycin Hemiface

    One randomly allocated hemiface received lesion-directed 308-nm excimer light twice weekly for 8 weeks in addition to the oral azithromycin received by all participants.

    Device: 308-nm Excimer Light · Drug: Azithromycin

  • Active comparator
    Oral Azithromycin Only Hemiface

    The contralateral hemiface received no excimer-light irradiation. All participants received oral azithromycin for 8 weeks.

    Drug: Azithromycin

Interventions

  • Device308-nm Excimer Light

    Monochromatic 308-nm excimer light was delivered using the KN-5000C device. Irradiation was lesion-directed and administered twice weekly for 8 weeks, with at least 48 hours between sessions, for a planned total of 16 sessions. Treatment began at 0.15 J/cm² and was increased according to erythema response and device dose settings, up to a maximum of 0.65 J/cm².

  • Description: Oral azithromycin 500 mg was administered after meals three times weekly for 8 weeks, corresponding to 24 scheduled doses.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Inflammatory-Lesion Count at Week 8

    Papules and pustules were counted separately for each hemiface by a blinded evaluator. Total inflammatory-lesion count was calculated as the sum of papules and pustules. Change was calculated as the baseline count minus the Week-8 count; positive values indicated improvement. The primary comparison was the within-participant difference in change between the excimer-treated and control hemifaces.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Change From Baseline in Papule Count at Week 8

    Papules were counted separately for each hemiface by a blinded evaluator. Change was calculated as the baseline count minus the Week-8 count; positive values indicated improvement.

    Time frame: Baseline and Week 8

  2. Change From Baseline in Pustule Count at Week 8

    Pustules were counted separately for each hemiface by a blinded evaluator. Change was calculated as the baseline count minus the Week-8 count; positive values indicated improvement.

    Time frame: Baseline and Week 8

  3. Percentage Reduction in Total Inflammatory-Lesion Count at Week 8

    Percentage reduction was calculated separately for each hemiface as 100 × (baseline total inflammatory-lesion count minus Week-8 total inflammatory-lesion count) divided by the baseline count. Higher percentages indicated greater improvement.

    Time frame: Baseline and Week 8

  4. Proportion of Hemifaces With at Least 50% Reduction in Total Inflammatory-Lesion Count

    A responder was defined as a hemiface achieving at least a 50% reduction in total inflammatory-lesion count from baseline to Week 8.

    Time frame: Baseline and Week 8

  5. Proportion of Hemifaces With at Least 80% Reduction in Total Inflammatory-Lesion Count

    A responder was defined as a hemiface achieving at least an 80% reduction in total inflammatory-lesion count from baseline to Week 8.

    Time frame: Baseline and Week 8

  6. Hemiface Investigator's Global Assessment Grade Over Time

    Acne severity was graded separately for each hemiface by a blinded evaluator using a five-category Investigator's Global Assessment scale ranging from 0 to 4, where 0 indicated clear skin and 4 indicated severe acne. Lower grades indicated lower acne severity.

    Time frame: Baseline, Week 4, Week 8, and Week 16

  7. Participant Satisfaction With Each Hemiface

    At Week 8, participants rated their satisfaction with each hemiface separately using an unvalidated numerical rating scale from 0 to 100. Higher scores indicated greater satisfaction.

    Time frame: Week 8

  8. Incidence of Solicited Local and Systemic Adverse Events

    Solicited local events included procedural pain, erythema, irritation, burning, dryness, blistering, and pigmentary alteration. Solicited systemic symptoms potentially associated with azithromycin included gastrointestinal symptoms, hypersensitivity reactions, palpitations, dizziness or syncope, and symptoms suggestive of hepatic dysfunction. Severity was classified as absent, mild, moderate, or severe.

    Time frame: From the first treatment through Week 16

07

Study locations

1 site
  • Al-Azhar University Hospital
    Damietta, Egypt
08

References and documents

Individual participant data

Plan to share: No — Deidentified individual participant data will not be shared because the original participant consent and institutional ethics framework did not prospectively authorize external sharing of participant-level data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Mar 2026, 4 months.

Of 58 non-industry interventional studies with no phase under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 17. This study's 4 months is below that.

Counting every sponsor, half of 120 studies reached it within 9 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2026
First posted
Aug 21, 2026
StartActual
Oct 12, 2025
Primary completionActual
Mar 10, 2026
CompletionActual
May 10, 2026
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07777952
Lead sponsor
Mahmoud Rageh
Responsible party
Mahmoud Rageh (Director of Venus Research Center, Venus Research Center) — Sponsor-investigator
First posted
Aug 21, 2026
Start date
Oct 12, 2025
Primary completion
Mar 10, 2026
Completion
May 10, 2026
Last update
Aug 21, 2026

Study contacts

Rabie B Atallah, MD
principal investigator · Al-Azhar University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion